Serenus Biotherapeutics to Launch Xenex UV Disinfection Robot at IPNET-K Conference 2015 in Naivasha, Kenya
Presentation Will Include New Clinical Trial Data on the Use of the Technology to Combat the Spread of Ebola
(firmenpresse) - NAIVASHA, KENYA -- (Marketwired) -- 11/15/15 -- Serenus Biotherapeutics, which is bridging the divide between the world''s leading healthcare markets and the growing demand for access to innovative drugs and devices in the emerging nations of Africa, today said it will launch the Xenex pulsed xenon Full-Spectrum™ ultraviolet (UV) room disinfection system at the Infection Prevention Network-Kenya, or IPNET-K Conference 2015 in Kenya.
Serenus will unveil the Xenex Germ-Zapping Robot™ during a presentation by Dr. Mark Stibich, co-founder and Chief Scientific Officer of Xenex, at the 4th IPNET-K Conference 2015. The conference, which is focusing on the theme of implementing infection prevention and control practices for a safer world, will be held November 17 to 22 at the Enasahipai Hotel in Naivasha, Kenya.
The Xenex Germ-Zapping Robot™ is an advanced UV disinfection robot used throughout hospitals, outpatient surgery centers and skilled nursing facilities in the United States, Canada and Europe. In a five minute disinfection cycle, the robot destroys contagious superbugs on surfaces through the use of high intensity pulsed xenon UV light. Designed for speed, effectiveness and ease of use, hospital cleaning staff efficiently integrate Xenex robots into a hospital''s existing operations and hospital acquired infection (HAI) reduction strategy.
"Hospital acquired infections represent a serious health threat in developing nations, where they prolong hospital stays and increase mortality rates. This problem is growing worse as pathogens'' resistance to antibiotics and the chemicals used in cleaning hospitals fuels an increase in drug resistant superbugs," said Dr. Menghis Bairu, CEO of Serenus. "We have an opportunity to make a substantial impact on the quality of healthcare in Africa with the Xenex pulsed xenon UV disinfection robot, which is proven technology that is saving lives by eliminating the deadly microorganisms that cause infections in the healthcare setting."
Dr. Stibich''s presentation on the Xenex technology will include new data on the ability of the Xenex Germ-Zapping Robot™ to kill the Ebola virus.
"Dangerous microorganisms lurk on high touch surfaces throughout healthcare facilities. Xenex''s pulsed xenon UV technology has been repeatedly proven to destroy the pathogens that make patients sick," said Dr. Stibich. "I''m looking forward to presenting the very successful results of our recent study on the Ebola virus at the IPNET-K conference, and to discussing how Xenex technology can and should be part of a hospital''s high risk pathogen response."
Serenus Biotherapeutics is a privately held healthcare company that specialises in late-stage drug development, in-licensing, registering, and commercialising drugs and devices approved in the United States, Europe, and Japan to address unmet medical needs with high regional prevalence in the Sub-Saharan African market. Serenus investors include Malin Corporation plc, an Irish-based global life sciences company. For more information, visit
Xenex''s patented Full Spectrum™ pulsed xenon UV room disinfection system is used for the advanced disinfection of healthcare facilities. Due to its speed and ease of use, the Xenex system has proven to integrate smoothly into hospital cleaning operations. The Xenex mission is to save lives and reduce suffering by eliminating the deadly microorganisms that cause hospital acquired infections. The company is backed by well-known investors that include Malin Corporation plc, Battery Ventures, Targeted Technology Fund II and RK Ventures. For more information visit
Xenex is the only UV disinfection company with multiple peer reviewed published outcome studies showing a reduction in infection rates when pulsed xenon UV technology is used to disinfect rooms. Recent peer reviewed studies by hospitals that purchased Xenex robots have reported greater than 56 percent decreases in methicillin-resistant Staphylococcus aureus (MRSA), 70 percent decreases in Clostridium difficile (C.diff) and 100% decreases in Surgical Site Infection rates, documenting how they used the Xenex robot in their real-world hospital environment to reduce infection rates by destroying the microorganisms that cause infections. Xenex offers the only technology that uses high intensity Full Spectrum™ pulsed xenon UV light to disinfect.
More than 300 healthcare facilities now include Xenex devices in infection control protocols throughout the United States, Canada and Europe. MD Anderson Cancer Center, the Central Texas Veterans Health Care System, Cooley Dickinson Health Care and other healthcare facilities have published 14 peer reviewed studies providing evidence of the Xenex robot''s efficacy in highly regarded scientific journals.
Contact:
For Serenus Biotherapeutics
Daniel Levine
Levine Media Group
(510) 280-5405
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 15.11.2015 - 21:53 Uhr
Sprache: Deutsch
News-ID 1399544
Anzahl Zeichen: 3942
contact information:
Contact person:
Town:
NAIVASHA, KENYA
Phone:
Kategorie:
Drugs
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 336 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Serenus Biotherapeutics to Launch Xenex UV Disinfection Robot at IPNET-K Conference 2015 in Naivasha, Kenya
"
steht unter der journalistisch-redaktionellen Verantwortung von
Serenus Biotherapeutics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
